title: The rate of visual field change in the ocular hypertension treatment study.
abstract: OBJECTIVE
  To assess the rate of change of visual field (VF) mean deviation (MD) in the Ocular Hypertension Treatment Study (OHTS).
  
  
  METHODS
  OHTS data were filtered to exclude eyes that had fewer than 10 reliable VFs or less than 5 years of follow-up or that reached a nonglaucomatous endpoint. The rate of change of MD (MDR) was calculated for each eye. Differences were sought between groups of eyes differing in primary open angle glaucoma (POAG) outcome, how POAG was determined, and original randomization.
  
  
  RESULTS
  In total, 2609 eyes (1379 participants) met the selection criteria. The mean MDR was -0.08 ± 0.20 dB/y (±SD). POAG eyes (n = 359) had significantly worse MDRs (-0.26 ± 0.36 dB/y) than non-POAG eyes (n = 2250; -0.05 ± 0.14 dB/y; P < 0.001). Eyes that reached POAG endpoints based on only VF change (n = 74; -0.29 ± 0.31 dB/y) or only optic disc change (n = 158; -0.12 ± 0.19 dB/y) had significantly worse MDRs than non-POAG eyes (both P < 0.001). Eyes that reached POAG endpoints for both VF and optic disc change (n = 127) deteriorated more rapidly (-0.42 ± 0.46 dB/y) than eyes showing only VF change (P = 0.017) or only optic disc change (P < 0.001). There was not a significant association between MDR and original OHTS randomization (observe vs. treat, P = 0.168).
  
  
  CONCLUSIONS
  Eyes that develop POAG have significantly worse MDRs than eyes that do not. Eyes that reached endpoints due to both VF and optic disc change had worse MDRs than eyes displaying change in only one of these. MDR was not significantly associated with randomization, suggesting that MDR may not be the best measure of VF change in early-stage POAG. (ClinicalTrials.gov number, NCT00000125.).
authors.affiliation: Devers Eye Institute, Legacy Research Institute, Portland, Oregon 97232, USA. sdemirel@deverseye.org
authors.forename: Shaban
authors.initials: S
authors.lastname: Demirel
authors.forename: Carlos Gustavo V
authors.initials: CG
authors.lastname: De Moraes
authors.forename: Stuart K
authors.initials: SK
authors.lastname: Gardiner
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Liebmann
authors.forename: George A
authors.initials: GA
authors.lastname: Cioffi
authors.forename: Robert
authors.initials: R
authors.lastname: Ritch
authors.forename: Mae O
authors.initials: MO
authors.lastname: Gordon
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kass
mesh_terms: D018450:Disease Progression; D005189:False Positive Reactions; D005902:Glaucoma, Open-Angle / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D009898:Optic Disk / Q000473:pathology; D009901:Optic Nerve Diseases / Q000503:physiopathology*; D011237:Predictive Value of Tests; D014786:Vision Disorders / Q000503:physiopathology*; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*